Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

Despite therapeutic advances, the long-term survival rates for acute myeloid leukemia (AML) are estimated to be 10% or less, pointing to the need for better treatment options. AML cells express the myeloid marker CD33, making it amenable to CD33-targeted therapy. Thus, the in vitro and in vivo anti-...

Full description

Saved in:
Bibliographic Details
Main Authors: Sutherland, May Kung, Yu, Changpu, Lewis, Timothy S, Miyamoto, Jamie B, Morris-Tilden, Carol A, Jonas, Mechthild, Sutherland, Jennifer, Nesterova, Albina, Gerber, Hans-Peter, Sievers, Eric L, Grewal, Iqbal S, Law, Che-Leung
Format: Artigo
Language:Inglês
Published: Landes Bioscience 2009
Subjects:
Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2759498/
https://ncbi.nlm.nih.gov/pubmed/20065652
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items